ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Impact of dialysis modality choice on the survival of end-stage renal disease patients with congestive heart failure in southern China: A retrospective cohort study

He, Zhiren; Liang, Hui; Huang, Jing; Zhang, Defei; Ma, Hongyan; Lin, Junjie; Cai, Youqing; Liu, Tonghuan; Li, Hucai; Qiu, Weizhong; Wang, Lingzheng; Yuan, Fengling; Hou, Haijing; Zhao, Daixin; Liu, Xusheng*; Wang, Lixin*广州中医药大学
Frontiers in Medicine2022-10-17DOI: 10.3389/fmed.2022.898650
8阅读
引用收藏
分享

摘要

Background and objectHeart failure is one of the common complications in patients with end-stage renal disease (ESRD) and a major cause of death in these patients. The choice of dialysis modality for ESRD patients with congestive heart failure (CHF) is still inconclusive. The purpose of this study was to compare the prognosis of hemodialysis (HD) and peritoneal dialysis (PD) among ESRD patients with CHF and provide a basis for clinical decision-making. Materials and methodsThis was a retrospective study conducted at Guangdong Provincial Hospital of Traditional Chinese Medicine that included patients with CHF requiring long-term renal replacement therapy between January 1, 2012 and December 31, 2017. The end of follow-up was December 31, 2020. All patients were divided into HD and PD groups and sub grouped by age, and we used univariate and multifactorial Cox regression analyses to calculate the relative hazard ratios (HR) of the different dialysis types and adjusted for differences in baseline data using propensity score matching (PSM). ResultA total of 121 patients with PD and 156 patients with HD were included in this study. Among younger ESRD patients (<= 65 years of age) with CHF, the prognosis of HD was worse than that of PD [HR = 1.84, 95% confidence interval (CI) = 1.01-3.34], and this disadvantage remained significant in the fully adjusted model [sex, age at dialysis initiation, Charlson comorbidities index, body mass index, prealbumin, hemoglobin, and left ventricular ejection fraction (LVEF)] and after PSM. In the older group (>65 years of age), the prognosis of HD was better than that of PD (HR = 0.46, 95% CI = 0.25-0.85), and the protective effect remained in the fully adjusted model and after PSM. The aforementioned survival differences across the cohort were maintained in patients with preserved LVEF (>55%), but could not be reproduced in patients with reduced LVEF (<= 55%). ConclusionIn southern China, PD is a better choice for younger patients with ESRD, CHF and preserved LVEF, and HD is the better option for older patients.

学科与关键词

关键词
all-cause mortalityhemodialysisperitoneal dialysis (PD)end-stage renal disease (ESRD)congestive heart failure (CHF)
相关
加载中…
  • Clinical Outcomes in Patients on Hemodialysis with Congestive Heart Failure
    Zhao, Xinju; Gan, Liangying; Niu, Qingyu; Hou, Fan Fan; Liang, Xinlin; Chen, Xiaonong; Chen, Yuqing; Zhao, Junhui; McCullough, Keith; Ni, Zhaohui*; Zuo, Li*Kidney Diseases, 2023, 9(4).
  • Propensity-matched comparison of mortality between peritoneal dialysis and hemodialysis in patients with type 2 diabetes
    Liu, Hui; He, Zhiren; Hu, Xiaoxuan; Li, Shaoxue; Wang, Lixin; Zhao, Daixin; Lin, Qizhan; Liu, Xusheng; Lu, Fuhua*; Zhang, Difei*INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54(6): 1373-1381.被引 2
  • Burden of kidney disease among patients with peritoneal dialysis versus conventional in-centre haemodialysis: A randomised, non-inferiority trial
    Fan, Li; Yang, Xiao; Chen, Qinkai; Zhang, Hao; Wang, Jianqin; Chen, Menghua; Peng, Hui; Ni, Zhaohui; Wan, Jianxin; Yang, Hongtao; Li, Yun; Wang, Li; Peng, Ai; Lin, Hongli; Zhang, Jinyuan; Shen, Huaying; Xiong, Fei; He, Yongcheng; Zha, Yan; Xie, Minyan; Jiao, Jundong; Jiang, Gengru; Zheng, Xunhuan; Xiao, Jun; Rong, Rong; Qian, Jiaqi; Yu, Xueqing*Peritoneal Dialysis International, 2022, 42(3): 246-258.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Medicine
发表日期
2022-10-17
卷期
第 9 卷
页码
898650
DOI
10.3389/fmed.2022.898650
期刊等级
3区
成果收录
SCIE

作者

  • H

    He, Zhiren (第一作者)

    2 · guangzhou univ chinese med

  • L

    Liang, Hui

    2 · guangzhou univ chinese med

查看全部 16 位作者收起作者
  • H

    Huang, Jing

    2 · guangzhou univ chinese med

  • Z

    Zhang, Defei

    2 · guangzhou univ chinese med

  • M

    Ma, Hongyan

    2 · guangzhou univ chinese med

  • L

    Lin, Junjie

    2 · guangzhou univ chinese med

  • C

    Cai, Youqing

    2 · guangzhou univ chinese med

  • L

    Liu, Tonghuan

    2 · guangzhou univ chinese med

  • L

    Li, Hucai

    2 · guangzhou univ chinese med

  • Q

    Qiu, Weizhong

    2 · guangzhou univ chinese med

  • W

    Wang, Lingzheng

    2 · guangzhou univ chinese med

  • Y

    Yuan, Fengling

    2 · guangzhou univ chinese med

  • H

    Hou, Haijing

    2 · guangzhou univ chinese med

  • Z

    Zhao, Daixin

    2 · guangzhou univ chinese med

  • L

    Liu, Xusheng (通讯)

    2 · guangzhou univ chinese med

  • W

    Wang, Lixin (通讯)

    2 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417